Literature DB >> 30612138

Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide.

Charles Thivolet1,2, Lucien Marchand3,4, Karim Chikh4,5.   

Abstract

AIMS/HYPOTHESIS: Recent studies have demonstrated that residual beta cells may be present in some people with long-standing type 1 diabetes, but little is known about the potential impact of this finding on alpha cell function and incretin levels. This study aimed to evaluate whether insulin microsecretion could modulate glucagon and glucagon-like peptide-1 (GLP-1) responses to a mixed meal tolerance test (MMTT).
METHODS: Adults with type 1 diabetes onset after the age of 15 years (n = 29) underwent a liquid MMTT after an overnight fast. Insulin microsecretion was defined when peak C-peptide levels were >30 pmol/l using an ultrasensitive assay. Four individuals with recent-onset type 1 diabetes were included as controls. Glucagon and GLP-1 responses were analysed according to C-peptide patterns.
RESULTS: We found comparable peak values, Δ0-max levels and AUCs of glucagon and GLP-1 responses in C-peptide-positive participants (n = 9) and C-peptide-negative participants (n = 16) with long-standing diabetes and in participants with recent-onset diabetes (n = 4). Mean glucagon levels, however, differed (p = 0.01). Mean GLP-1 responses were significantly lower according to C-peptide positivity (p < 0.001, ANOVA). Interestingly, GLP-1 levels correlated to glucagon values in C-peptide-positive participants with long-standing diabetes (Pearson's r = 0.915, p = 0.004) and in participants with recent-onset diabetes (p < 0.001) but not in C-peptide-negative participants. CONCLUSIONS/
INTERPRETATION: The glucagon response to an MMTT in people with long-standing type 1 diabetes is not reduced by the presence of residual beta cells. The reduction of GLP-1 responses according to residual C-peptide levels suggests specific regulatory pathways.

Entities:  

Keywords:  Incretins; Insulin microsecretion; Pancreatic alpha cells; Type 1 diabetes

Mesh:

Substances:

Year:  2019        PMID: 30612138     DOI: 10.1007/s00125-018-4804-y

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  12 in total

1.  Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease.

Authors:  Mark A Atkinson; Matthias von Herrath; Alvin C Powers; Michael Clare-Salzler
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

Review 2.  Type I diabetes mellitus. A chronic autoimmune disease.

Authors:  G S Eisenbarth
Journal:  N Engl J Med       Date:  1986-05-22       Impact factor: 91.245

3.  Unique arrangement of alpha- and beta-cells in human islets of Langerhans.

Authors:  Domenico Bosco; Mathieu Armanet; Philippe Morel; Nadja Niclauss; Antonino Sgroi; Yannick D Muller; Laurianne Giovannoni; Géraldine Parnaud; Thierry Berney
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

4.  A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets.

Authors:  P Marchetti; R Lupi; M Bugliani; C L Kirkpatrick; G Sebastiani; F A Grieco; S Del Guerra; V D'Aleo; S Piro; L Marselli; U Boggi; F Filipponi; L Tinti; L Salvini; C B Wollheim; F Purrello; F Dotta
Journal:  Diabetologia       Date:  2012-09-11       Impact factor: 10.122

5.  Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.

Authors:  Chantal Mathieu; Bernard Zinman; Joanna Uddén Hemmingsson; Vincent Woo; Peter Colman; Erik Christiansen; Martin Linder; Bruce Bode
Journal:  Diabetes Care       Date:  2016-08-09       Impact factor: 19.112

6.  Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.

Authors:  J Dupre; M T Behme; I M Hramiak; P McFarlane; M P Williamson; P Zabel; T J McDonald
Journal:  Diabetes       Date:  1995-06       Impact factor: 9.461

7.  Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia.

Authors:  Caroline K Kramer; Carla A Borgoño; Paula Van Nostrand; Ravi Retnakaran; Bernard Zinman
Journal:  Diabetes Care       Date:  2013-11-15       Impact factor: 19.112

8.  Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.

Authors:  Kristine J Hare; Tina Vilsbøll; Jens J Holst; Filip K Knop
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-01-26       Impact factor: 4.310

9.  Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay.

Authors:  Limei Wang; Nicholas Fraser Lovejoy; Denise L Faustman
Journal:  Diabetes Care       Date:  2012-03       Impact factor: 19.112

10.  The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells.

Authors:  Richard A Oram; Angus G Jones; Rachel E J Besser; Bridget A Knight; Beverley M Shields; Richard J Brown; Andrew T Hattersley; Timothy J McDonald
Journal:  Diabetologia       Date:  2014-01       Impact factor: 10.122

View more
  9 in total

Review 1.  When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD.

Authors:  Alba Rojano-Toimil; Jesús Rivera-Esteban; Ramiro Manzano-Nuñez; Juan Bañares; David Martinez Selva; Pablo Gabriel-Medina; Roser Ferrer; Juan M Pericàs; Andreea Ciudin
Journal:  J Clin Med       Date:  2022-06-08       Impact factor: 4.964

2.  High residual C-peptide likely contributes to glycemic control in type 1 diabetes.

Authors:  Michael R Rickels; Carmella Evans-Molina; Henry T Bahnson; Alyssa Ylescupidez; Kristen J Nadeau; Wei Hao; Mark A Clements; Jennifer L Sherr; Richard E Pratley; Tamara S Hannon; Viral N Shah; Kellee M Miller; Carla J Greenbaum
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 3.  The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review.

Authors:  Keyu Guo; Qi Tian; Lin Yang; Zhiguang Zhou
Journal:  Diabetes Metab Syndr Obes       Date:  2021-12-21       Impact factor: 3.168

4.  Insulin Requirement and Complications Associated With Serum C-Peptide Decline in Patients With Type 1 Diabetes Mellitus During 15 Years After Diagnosis.

Authors:  Junghwan Suh; Hae In Lee; Myeongseob Lee; Kyungchul Song; Han Saem Choi; Ahreum Kwon; Ho-Seong Kim; Hyun Wook Chae
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-19       Impact factor: 6.055

5.  How low is really low? Comparison of two C-peptide assays to establish residual C-peptide production in type 1 diabetes.

Authors:  Kitty de Leur; Charlotte Vollenbrock; Pim Dekker; Martine de Vries; Erwin Birnie; Dick Mul; Bruce H R Wolffenbuttel; Joost Groen; Henk-Jan Aanstoot; Lianne Boesten
Journal:  Diabet Med       Date:  2022-01-17       Impact factor: 4.213

Review 6.  C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective.

Authors:  Ernesto Maddaloni; Geremia B Bolli; Brian M Frier; Randie R Little; Richard D Leslie; Paolo Pozzilli; Raffaela Buzzetti
Journal:  Diabetes Obes Metab       Date:  2022-06-28       Impact factor: 6.408

7.  Postexercise Glycemic Control in Type 1 Diabetes Is Associated With Residual β-Cell Function.

Authors:  Guy S Taylor; Kieran Smith; Tess E Capper; Jadine H Scragg; Ayat Bashir; Anneliese Flatt; Emma J Stevenson; Timothy J McDonald; Richard A Oram; James A Shaw; Daniel J West
Journal:  Diabetes Care       Date:  2020-08-03       Impact factor: 19.112

Review 8.  Cell Heterogeneity and Paracrine Interactions in Human Islet Function: A Perspective Focused in β-Cell Regeneration Strategies.

Authors:  Eva Bru-Tari; Daniel Oropeza; Pedro L Herrera
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-03       Impact factor: 5.555

9.  Impact of glucagon response on early postprandial glucose excursions irrespective of residual β-cell function in type 1 diabetes: A cross-sectional study using a mixed meal tolerance test.

Authors:  Ayako Ito; Ichiro Horie; Masaki Miwa; Ayaka Sako; Tetsuro Niri; Yomi Nakashima; Riyoko Shigeno; Ai Haraguchi; Shoko Natsuda; Satoru Akazawa; Akie Kamada; Atsushi Kawakami; Norio Abiru
Journal:  J Diabetes Investig       Date:  2021-01-22       Impact factor: 4.232

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.